281 related articles for article (PubMed ID: 28460165)
21. Novel in situ self-assembly nanoparticles for formulating a poorly water-soluble drug in oral solid granules, improving stability, palatability, and bioavailability.
Guo S; Pham K; Li D; Penzak SR; Dong X
Int J Nanomedicine; 2016; 11():1451-60. PubMed ID: 27103803
[TBL] [Abstract][Full Text] [Related]
22. Formulation and evaluation of a folic acid receptor-targeted oral vancomycin liposomal dosage form.
Anderson KE; Eliot LA; Stevenson BR; Rogers JA
Pharm Res; 2001 Mar; 18(3):316-22. PubMed ID: 11442271
[TBL] [Abstract][Full Text] [Related]
23. In vitro comparison of liposomal drug delivery systems targeting the oxytocin receptor: a potential novel treatment for obstetric complications.
Hua S; Vaughan B
Int J Nanomedicine; 2019; 14():2191-2206. PubMed ID: 30988616
[TBL] [Abstract][Full Text] [Related]
24. Th1 immune responses can be modulated by varying dimethyldioctadecylammonium and distearoyl-sn-glycero-3-phosphocholine content in liposomal adjuvants.
Hussain MJ; Wilkinson A; Bramwell VW; Christensen D; Perrie Y
J Pharm Pharmacol; 2014 Mar; 66(3):358-66. PubMed ID: 24251796
[TBL] [Abstract][Full Text] [Related]
25. A Study of Liposomal Formulations to Improve the Delivery of Aquated Cisplatin to a Multidrug Resistant Tumor.
Zhao Y; May JP; Chen IW; Undzys E; Li SD
Pharm Res; 2015 Oct; 32(10):3261-8. PubMed ID: 25964047
[TBL] [Abstract][Full Text] [Related]
26. Combined strategies for liposome characterization during in vitro digestion.
Hermida LG; Sabés-Xamaní M; Barnadas-Rodríguez R
J Liposome Res; 2009; 19(3):207-19. PubMed ID: 19548842
[TBL] [Abstract][Full Text] [Related]
27. Liposome-encapsulated midazolam for oral administration.
Tomoyasu Y; Yasuda T; Maeda S; Higuchi H; Miyawaki T
J Liposome Res; 2011 Jun; 21(2):166-72. PubMed ID: 20684674
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic and Protective Effects of Liposomal Encapsulation of Astaxanthin in Mice with Alcoholic Liver Fibrosis.
Wu YC; Huang HH; Wu YJ; Manousakas I; Yang CC; Kuo SM
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31434227
[TBL] [Abstract][Full Text] [Related]
29. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
[TBL] [Abstract][Full Text] [Related]
30. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics.
Deniz A; Sade A; Severcan F; Keskin D; Tezcaner A; Banerjee S
Biosci Rep; 2010 Jun; 30(5):365-73. PubMed ID: 19900165
[TBL] [Abstract][Full Text] [Related]
31. Liposomal Incorporation to Improve Dissolution and Stability of Rosmarinic Acid and Carvacrol Extracted from Oregano (
Baranauskaite J; Duman G; Corapcıoğlu G; Baranauskas A; Taralp A; Ivanauskas L; Bernatoniene J
Biomed Res Int; 2018; 2018():6147315. PubMed ID: 30140697
[TBL] [Abstract][Full Text] [Related]
32. Formulation and evaluation of Pheroid vesicles containing mefloquine for the treatment of malaria.
du Plessis LH; Helena C; van Huysteen E; Wiesner L; Kotzé AF
J Pharm Pharmacol; 2014 Jan; 66(1):14-22. PubMed ID: 24117456
[TBL] [Abstract][Full Text] [Related]
33. Development of a stable single-vial liposomal formulation for vincristine.
Mao W; Wu F; Lee RJ; Lu W; Wang J
Int J Nanomedicine; 2019; 14():4461-4474. PubMed ID: 31296986
[No Abstract] [Full Text] [Related]
34. Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration.
Chaudhury A; Das S; Lee RF; Tan KB; Ng WK; Tan RB; Chiu GN
Int J Pharm; 2012 Jul; 430(1-2):167-75. PubMed ID: 22537806
[TBL] [Abstract][Full Text] [Related]
35. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.
Ramsay E; Alnajim J; Anantha M; Zastre J; Yan H; Webb M; Waterhouse D; Bally M
Eur J Pharm Biopharm; 2008 Mar; 68(3):607-17. PubMed ID: 17904831
[TBL] [Abstract][Full Text] [Related]
36. Formulation kit for liposomal doxorubicin composed of lyophilized liposomes.
Stevens PJ; Lee RJ
Anticancer Res; 2003; 23(1A):439-42. PubMed ID: 12680245
[TBL] [Abstract][Full Text] [Related]
37. Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy.
Liu J; Lee H; Huesca M; Young A; Allen C
Cancer Chemother Pharmacol; 2006 Sep; 58(3):306-18. PubMed ID: 16333677
[TBL] [Abstract][Full Text] [Related]
38. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
[TBL] [Abstract][Full Text] [Related]
39. Bile salt liposomes for enhanced lymphatic transport and oral bioavailability of paclitaxel.
Zhang B; Xue A; Zhang C; Yu J; Chen W; Sun D
Pharmazie; 2016 Jun; 71(6):320-6. PubMed ID: 27455550
[TBL] [Abstract][Full Text] [Related]
40. Poly(ethylene glycol)-induced and temperature-dependent phase separation in fluid binary phospholipid membranes.
Lehtonen JY; Kinnunen PK
Biophys J; 1995 Feb; 68(2):525-35. PubMed ID: 7696506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
